Published in Gene Therapy Weekly, October 30th, 2003
"CalbaTech's acquisition of Molecula, a private company, allows us to move forward with our strategic plan for the RNAi market," said Matt Maupin, CEO of Molecula. The company's technology permits delivery of active siRNA or antisense to target genes with a high rate of success. Design technology and experience...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.